 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
17 News |  |
- | LHW090 / Novartis
Trial completion: Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function (clinicaltrials.gov) - Oct 25, 2018
P2, N=84, Completed, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed
- | LHW090 / Novartis
Enrollment closed: Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function (clinicaltrials.gov) - Sep 18, 2018
P2, N=84, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || LHW090 / Novartis
Enrollment change: Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function (clinicaltrials.gov) - May 30, 2018
P2, N=84, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting N=40 --> 84
- LHW090 / Novartis
Trial primary completion date: Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function (clinicaltrials.gov) - Sep 14, 2017
P2, N=40, Recruiting, Sponsor: Novartis Pharmaceuticals
N=40 --> 84 Trial primary completion date: Apr 2018 --> Aug 2018
- |||| LHW090 / Novartis
Trial completion, Enrollment change: Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients (clinicaltrials.gov) - Sep 13, 2017
P2, N=57, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Apr 2018 --> Aug 2018 Recruiting --> Completed | N=80 --> 57
- | LHW090 / Novartis
Enrollment open: Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function (clinicaltrials.gov) - Mar 24, 2017
P2, N=40, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=80 --> 57 Not yet recruiting --> Recruiting
- || LHW090 / Novartis
Trial primary completion date: Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients (clinicaltrials.gov) - Sep 21, 2016
P2, N=80, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2017 --> Jul 2017
- | LHW090 / Novartis
Trial initiation date, Trial primary completion date: Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function (clinicaltrials.gov) - Mar 9, 2016
P2, N=40, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Feb 2017 --> Jul 2017 Initiation date: Mar 2016 --> Mar 2017 | Trial primary completion date: Dec 2016 --> Dec 2017
- | LHW090 / Novartis
New P2 trial: Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function (clinicaltrials.gov) - Feb 9, 2016
P2, N=40, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- |||| LHW090 / Novartis
Enrollment open, Trial primary completion date: Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients (clinicaltrials.gov) - Nov 21, 2015
P2, N=80, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Mar 2016 --> Mar 2017 | Trial primary completion date: Dec 2016 --> Dec 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2016 --> Feb 2017
- ||||| LHW090 / Novartis
New P2 trial: Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients (clinicaltrials.gov) - Aug 4, 2015
P2, N=80, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||| LHW090 / Novartis
Trial completion: An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction (clinicaltrials.gov) - Aug 28, 2014
P1, N=205, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Trial primary completion date: Oct 2016 --> Feb 2017 Recruiting --> Completed
- || LHW090 / Novartis
Trial primary completion date: An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction (clinicaltrials.gov) - Jun 13, 2014
P1, N=244, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Trial primary completion date: Dec 2013 --> Jul 2014
- || LHW090 / Novartis
Enrollment change: An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction (clinicaltrials.gov) - Nov 20, 2013
P1, N=220, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2013 --> Jul 2014 N=144 --> 220
- ||| LHW090 / Novartis
New P1 trial: An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction (clinicaltrials.gov) - May 1, 2013
P1, N=220, Recruiting, Sponsor: Novartis Pharmaceuticals